Edwards Lifesciences announced it has exercised its option to acquire Innovalve Bio Medical, an early-stage transcatheter mitral valve replacement TMVR company, following its initial investment in 2017. Since that time, Innovalve has demonstrated progress in its program with promising early clinical experience. Combined with Edwards’ existing mitral innovations, the acquisition enhances the company’s TMVR technologies to address large unmet structural heart patient needs and support sustainable long-term growth. Innovalve will join the transcatheter mitral and tricuspid therapies TMTT product group, led by corporate vice president, Daveen Chopra…The acquisition is expected to close by the end of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences Welcomes Dr. Feinberg to Board
- Edwards Lifesciences price target raised to $106 from $105 at Citi
- Uber, Birkenstock among additions to Deutsche Bank ‘Fresh Money List’ for Q3
- Edwards Lifesciences price target raised to $91 from $89 at Evercore ISI
- Edwards Lifesciences Announces Senior Financial Leadership Transition
Questions or Comments about the article? Write to editor@tipranks.com